TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00609284
Drug: Carboplatin, 5FU concomitant
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 70mg/m²/D ; 5FU 600 mg/m²/D, D1-4, D22-25, D43-46
Study: NCT00854802
Drug: Debio 025
Normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debio 025 supplied in soft gel capsules
Study: NCT00854802
Drug: Peg-IFNα2a
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-IFNα2a supplied in pre-filled syringes
Study: NCT00854802
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin supplied in tablets
Study: NCT04104984
Drug: Progesterone Vaginal Suppository
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a progesterone vaginal suppository to prevent preterm labour
Study: NCT02065713
Drug: Golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prefilled syringe with golimumab 50mg (Simponi®) administrated subcutaneously, once monthly, for 24 weeks.
Study: NCT05712642
Drug: Intravitreal Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Serum systemic level of VEGF was measured before and after 1 week and 4 weeks of intravitreal injection of bevacizumab
Study: NCT04351230
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01579760
Drug: Aflibercept every 2 months
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2.0 mg aflibercept intravitreal injections once per month for the first 3 months (M0, M1, M2), then every 2 months (M4, M6, M8, M10)
Study: NCT01579760
Drug: Aflibercept monthly
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2.0mg aflibercept intravitreal injections every month (M0-11)
Study: NCT03887416
Drug: Dapagliflozin 10 MG Oral Tablet [Farxiga]
Normalized name: dapagliflozin 10 MG Oral Tablet [Farxiga]
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The investigational medicinal product (IMP) is dapagliflozin10 mg given once daily (film coated tablets, oral use).~Dapagliflozin will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: 10 mg, Green, plain, diamond shaped, film coated tablet (orally)
Study: NCT04781114
Drug: JS002
Normalized name: Immunoglobulin g4, anti-(neural apoptosis-regulated convertase 1) (human monoclonal js002 .gamma.4-chain), disulfide with human monoclonal js002 .kappa.-chain, dimer
DrugBank: Ongericimab (DB18949)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS002: 150mg(1mL) Q2W; Placebo 1mL Q2W.
Study: NCT02780167
Drug: PF-04965842
Normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg of PF-04965842 QD for 12 weeks
Study: NCT02780167
Drug: PF-04965842
Normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30 mg of PF-04965842 QD for 12 weeks
Study: NCT02780167
Drug: PF-04965842
Normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg of PF-04965842 QD for 12 weeks
Study: NCT02780167
Drug: PF-04965842
Normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg of PF-04965842 QD for 12 weeks
Study: NCT03235479
Drug: Rimegepant
Normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg tablet QD
Study: NCT01048502
Drug: Fenofibrate (Tricor) tablets
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks
Study: NCT01048502
Drug: Lovaza
Normalized name: Lovaza
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.
Study: NCT03527251
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.
Study: NCT03527251
Drug: SHR-1210
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.
Study: NCT01089621
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg to 120 mg administered orally, daily for 12 weeks
Study: NCT02278458
Drug: icotinib
Normalized name: icotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
Study: NCT02278458
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
Study: NCT03662763
Drug: Extended-release Guanfacine Hydrochloride (SPD503)
Normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dosing in all subjects will initiate with 1mg/day, and may be increased by 1 mg increments after a minimum of 1 week on the current dose to the maximum doses based on age and weight.
Study: NCT01954914
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.
Study: NCT00467831
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan potassium tablet, 25 mg by mouth every night at bedtime.
Study: NCT00467831
Drug: Zileuton
Normalized name: Zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zileuton tablet, 1200 mg by mouth twice daily.
Study: NCT00467831
Drug: N-Acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine solution, 600 mg by mouth three times daily.
Study: NCT02414373
Drug: Ropivacaine 2mg/ml
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: local anesthetics, which will epidurally administered
Study: NCT02414373
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: local anesthetics, which will epidurally administered
Study: NCT02067767
Drug: Abacavir/Lamivudine/Dolutegravir
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: At Day 1 (D1):~* group 1 will switch their ongoing treatment of ABC/3TC + NVP to ABC/3TC/DTG ;~* group 2 will continue NVP and switch ABC/3TC to ABC/3TC/DTG for 6 days (D-5 to D0), then stop NVP from D1.
Study: NCT03553875
Drug: Memantine Hydrochloride
Normalized name: Memantine Hydrochloride
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to memantine for the course of the 12-week randomized controlled trial (RCT).
Study: NCT01754987
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01076556
Drug: Alvocidib Hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Alvocidib (DB03496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03700645
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol
Study: NCT02251977
Drug: GM1
Normalized name: pGM169/GL67A
DrugBank: pGM169/GL67A (DB17917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of GM1 for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
Study: NCT04532957
Drug: KBP-7072
Normalized name: KBP-COVID-19
DrugBank: KBP-COVID-19 (DB15858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD oral capsules
Study: NCT04448496
Drug: Dexamethasone implant
Normalized name: dexamethasone Drug Implant
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 0.7mg is injected into the vitreous cavity through the pars plana using applicator for diabetic macular edema.
Study: NCT04420624
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg (or 0.5mg) tablet of colchicine taken once a day for 1 month
Study: NCT02605252
Drug: Peginterferon alfa-2b
Normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peginterferon alfa-2b 80 micrograms/week for 48 weeks
Study: NCT02266394
Drug: Mesenchymal stem cell
Normalized name: Human mesenchymal stem cell
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-arterial infusion of the single-dose MSC
Study: NCT03923231
Drug: Atazanavir 300mg/ Ritonavir 100 mg once daily
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care
Study: NCT03923231
Drug: Atazanavir 250 mg / ritonavir 80 mg
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care. This dose of 250/ 80 is for participants weighing between 15 and 25 Kg
Study: NCT03812991
Drug: Miacalcin Calcitonin Salmon Nasal Spray
Normalized name: salmon calcitonin Nasal Spray [Miacalcin]
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miacalcin nasal spray is 1 spray (200 International Units) per day administered intranasally, alternating nostrils daily
Study: NCT00670033
Drug: Travoprost ophthalmic solution (new formulation)
Normalized name: travoprost Ophthalmic Solution
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00670033
Drug: Travoprost ophthalmic solution, 0.004%
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00479388
Drug: niacin (+) laropiprant
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of ER niacin/ laropiprant (1g); titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
Study: NCT00452608
Drug: atorvastatina
Normalized name: atorvastatina
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatina 80 mg/day by mouth for 10 days
Study: NCT01884688
Drug: ENK Cell Infusion
Normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 0(1 dose) ENK Cell Infusion Day 0 to + 12 (13 doses) Aldesleukin (IL2), 3x10 IU
Study: NCT03984045
Drug: Lidocaine topical
Normalized name: lidocaine topical
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal 2% lidocaine delivered directly to SPG
Study: NCT03984045
Drug: Prochlorperazine Injection
Normalized name: prochlorperazine Injection
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous prochlorperazine at 0.15mg/kg max 10 mg
Study: NCT01931527
Drug: Rasburicase
Normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
Study: NCT02018094
Drug: Iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-operative skin preparation prior to incision to skin.
Study: NCT02018094
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course
Study: NCT02018094
Drug: Chlorhexidine
Normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcoholic Chlorhexidine skin pre-op preparation
Study: NCT02018094
Drug: Teicoplanin
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days
Study: NCT00017394
Drug: vinorelbine tartrate
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00990847
Drug: Procaterol, Salbultamol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01320020
Drug: catumaxomab
Normalized name: catumaxomab
DrugBank: Catumaxomab (DB06607)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inter patient dose escalation 2 µg, 4 µg, 7 µg, 10 µg, 14 µg and 19 µg qwk corresponding to dose increments of 100%, 75%, 43%, 40% and 36% respectively of the previous dose
Study: NCT01215799
Drug: Bafetinib
Normalized name: Bafetinib
DrugBank: Bafetinib (DB11851)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bafetinib 240 mg bid
Study: NCT02787317
Drug: bivalirudin
Normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention.
Study: NCT02138292
Drug: Trametinib (2mg)/Digoxin (.25mg)
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Trametinib (2mg) will be administered orally on a daily basis.~2. Digoxin (0.25mg) will be administered orally on a daily basis.~On a 8 week cycle, duration of treatment can last from 8 to 104 weeks.
Study: NCT00261131
Drug: Botulinum Toxin A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT00572117
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Medication will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
Study: NCT00052416
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02111850
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days -7 to -3: Fludarabine 25 mg/m\^2 /day intravenous piggy-back (IVPB) daily over 30 minutes for 5 days.
Study: NCT02377921
Drug: aceneuramic acid extended-release (Ace-ER)
Normalized name: aceneuramic acid
DrugBank: Aceneuramic acid (DB11797)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets for oral use
Study: NCT04608799
Drug: Perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Efficacy of epilepsy drugs
Study: NCT02485821
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00206102
Drug: quetiapine fumarate
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: flexible dose oral
Study: NCT00206102
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: flexible dose oral
Study: NCT03204474
Drug: Lacosamide (LCM) tablet
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
Study: NCT03204474
Drug: Lacosamide (LCM) solution for infusion
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment B: Single dose of Lacosamide (LCM) 200 mg administered as intravenous infusion
Study: NCT01594047
Drug: ketamine infusion
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery
Study: NCT01594047
Drug: Methadone PCA
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methadone administered by a PCA system (dose 2 mg, lock-out 12min.)
Study: NCT01901172
Drug: posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Multiple doses Days 8-14
Study: NCT02092883
Drug: ACTH
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PK PET scan before and after ACTH treatment
Study: NCT00026052
Drug: riluzole
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03052972
Drug: Flortaucipir F18
Normalized name: Flortaucipir
DrugBank: Flortaucipir (DB15033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 370 megabecquerel (MBq)(10 millicurie \[mCi\]) single dose
Study: NCT00987831
Drug: Group A SLE prospective study
Normalized name: meningococcal group A polysaccharide
DrugBank: Meningococcal polysaccharide vaccine group A (DB13889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients have history and physical exmamination at each visit. Blood is drawn at each visit. At baseline, any background immune suppressant is stopped and patients given depomedrol up to 160 mg IM which can be repeated up to four times in the first two weeks. Patients are seen again at week 2, 4 and monthly until the final flare visit at which time they donate blood, receive appropriate treatments and exit study. Patients may elect to continue in study for up to one year. The following disease activity measures are included: SLEDAI, BILAG, CLASI, PGA, PROs (including lupus PRO and SF-36 ant ptGA), joint counts, exploratory outcome measures,BICLA,SRI
Study: NCT02194023
Drug: PAT
Normalized name: PAT
DrugBank: Fenamole (DB12506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were asked to rinse every 12 hours, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
Study: NCT03705949
Drug: Sodium Hyaluronate 0.1% drops
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be administered Drops of Sodium Hyaluronate 0.1% quid
Study: NCT03705949
Drug: Sodium Hyaluronate 0.2% drops
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be administered Drops of Sodium Hyaluronate 0.2% quid
Study: NCT00648024
Drug: Anagrelide Hydrochloride Capsules 1 mg
Normalized name: Anagrelide Hydrochloride
DrugBank: Anagrelide (DB00261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1mg, single dose fasting
Study: NCT03163849
Drug: Sofosbuvir , daclatasvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets
Study: NCT00248170
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg tablets
Study: NCT00248170
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg tablets
Study: NCT01463150
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 150mg per day for 15 days
Study: NCT01463150
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prasugrel 5mg per day for 15 days
Study: NCT03123783
Drug: APX005M
Normalized name: CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M
DrugBank: Sotigalimab (DB16413)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APX005M is a CD40 agonistic monoclonal antibody
Study: NCT03123783
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is an immune checkpoint (PD-1) blocking antibody
Study: NCT01198834
Drug: MRX-7EAT
Normalized name: MRx-4DP0004
DrugBank: MRx-4DP0004 (DB15751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of up to two patches at the discretion of the investigator for up to 7 days.
Study: NCT01198834
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application of up to two patches at the discretion of the investigator for up to 7 days.
Study: NCT02378441
Drug: Atorvastatin 20mg and Metformin SR 750mg
Normalized name: atorvastatin 20 MG
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: co-administration of Atorvastatin 20mg and Metformin SR 750mg
Study: NCT03103074
Drug: Botulinum B Toxin
Normalized name: Botulinum B toxin
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injections
Study: NCT02843659
Drug: BMS-931699
Normalized name: BMS-931699
DrugBank: Lulizumab pegol (DB15441)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT02843659
Drug: BMS-986142
Normalized name: BMS-986142
DrugBank: BMS-986142 (DB15291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days